Molecular Partners AG (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
MOLN Nasdaq 8731 https://www.molecularpartners.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Molecular Partners AG (ADR)

Life Science Cares Launches in Switzerland - Apr 19th, 2024 3:12 pm
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting - Apr 17th, 2024 3:12 pm
Molecular Partners Publishes Invitation to Annual General Meeting 2024 - Mar 26th, 2024 1:26 pm
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023 - Mar 14th, 2024 8:00 pm
The past three years for Molecular Partners (VTX:MOLN) investors has not been profitable - Mar 13th, 2024 8:58 am
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations - Mar 1st, 2024 9:00 pm
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference - Jan 7th, 2024 9:00 pm
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies - Jan 5th, 2024 9:00 pm
Retail investors account for 43% of Molecular Partners AG's (VTX:MOLN) ownership, while hedge funds account for 33% - Dec 22nd, 2023 7:22 am
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences - Dec 14th, 2023 6:00 am
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting - Dec 10th, 2023 5:00 pm
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS) - Nov 14th, 2023 6:00 am
We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate - Nov 9th, 2023 1:47 pm
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting - Nov 3rd, 2023 4:00 pm
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition - Nov 2nd, 2023 6:00 am
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit - Nov 1st, 2023 6:00 am
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio - Oct 26th, 2023 8:00 pm
Shareholders in Molecular Partners (VTX:MOLN) are in the red if they invested five years ago - Oct 5th, 2023 8:14 am
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting - Sep 13th, 2023 5:00 am
Molecular Partners Reports H1 2023 Corporate Highlights and Financials - Aug 24th, 2023 8:00 pm